EMA Authorised: Inovelon (rufinamide) — Eisai GmbH

View source ↗

Summary

EMA authorised Inovelon (rufinamide) by Eisai GmbH for epilepsy, following a decision on 28 November 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Lennox-gastaut Syndrome

Drugs mentioned

• Inovelon (rufinamide)

Snippet

Status: Authorised. Therapeutic area: Epilepsy. MAH: Eisai GmbH. Decision date: 28/11/2023